University of Pittsburgh researchers have successfully prompted the immune system to go after colon cancer in its earliest stages for those at high risk. The results of a clinical trial show that colon cancer may be the newest target for an effective anti-cancer vaccine.
They reported the promising results of the first human clinical trials to prevent colon cancer with a vaccine in the January issue of the journal Cancer Prevention Research. The study was partially funded by the National Cancer Institute and the National Institutes of Health.
Colorectal cancer is the No. 3 cause of cancer deaths in the United States, striking more than 100,000 Americans each year, according to the American Cancer Society, which says that over a lifetime an individual has a 5 percent chance of developing it. Each year, nearly 52,000 die from it.
"This prophylactic colon cancer vaccine boosts the patient's natural immune surveillance, which potentially could lead to the elimination of premalignant lesions before their progression to cancer," said Olivera Finn, distinguished professor and chair of the Department of Immunology at Pitt's School of Medicine, who is also the vaccine's developer, in a written statement. "This might spare patients the risk and inconvenience of repeated invasive surveillance tests, such as colonoscopy, that currently are used to spot and remove precancerous polyps."
For the study, the researchers tested the vaccine in patients who had a previous history of a well-developed precancerous polyp, called an advanced adenoma, which is how colon cancer typically develops. When such polyps are found, they are removed so they cannot become cancerous.
"Around 30 to 40 percent of these patients will develop a new polyp within three years," Dr. Robert E. Schoen, professor of medicine and epidemiology in Pitt's Division of Gastroenterology, Hepatology and Nutrition and the study's clinical leader, said. "In this study, we demonstrated the ability of the vaccine to boost immunity. Subsequent trials need to evaluate the vaccine for its ability to lower or prevent polyp recurrence and thus progression to colon cancer."
According to the university's explanation, the Pitt vaccine targets an abnormal variant of a protein called MUC1 that the cell itself makes. In advanced adenomas and in cancer, that protein is made with great abundance. MUC1, it noted, is also abnormally present in pancreatic, breast, lung and prostate cancer, which may mean a vaccine that targets it will have impact there, as well.
Business Insider said plans were in the works to test the vaccine against those cancers, too.
The Pittsburgh team tested the vaccine in 39 patients ages 40 to 70 that did not have cancer, but did have a history of the polyps. "It produced a strong protective response in 17 of the patients, or 44 percent," they said in a news release on the study. "Researchers said the lack of response in the other 22 patients was likely due to already high levels of cells that suppress the immune system's ability to fight cancer."
Finn theorized that it might be better to vaccinate people against colon cancer at even earlier stages or only vaccinate those without an already-suppressed immune system.
In the study, patients received an initial dose, then more shots of vaccine two and 10 weeks later. Blood tests showed the response at those times, and at 12 weeks, 28 weeks and a year. At that point, a booster shot was given to "confirm the durability of the immune response."
There were few side effects reported and they were mild, the researchers noted. Safety was previously shown in patients with pancreatic cancer.
- 50 things you might not know about 15 of your...
- LDS missionaries developing strategies to...
- Judge orders Colo. cake-maker to serve gay...
- Pearl Harbor ceremony marks bombing...
- Nelson Mandela's faith made him a worldwide...
- 'Deseret News Sunday Edition' looks at Sharia...
- Report: German president boycotting Sochi...
- Food-tech startups aim to replace eggs and...
- Obama: Income inequality a defining... 108
- Judge orders Colo. cake-maker to serve... 102
- LDS missionaries developing strategies... 63
- Fast-food strikes return amid push for... 31
- Colorado court hears discrimination... 30
- Utahns react to death of Nelson Mandela 26
- Research: Native American genes have... 23
- Obama administration will allow green... 17